Diabetic Nephropathy - Pipeline Review, H1 2018

  • ID: 4473131
  • Drug Pipelines
  • 232 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • CSL Ltd
  • Gilead Sciences Inc
  • Merck & Co Inc
  • PhiloGene Inc
  • MORE
Diabetic Nephropathy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2018, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 15, 13, 1, 30, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • CSL Ltd
  • Gilead Sciences Inc
  • Merck & Co Inc
  • PhiloGene Inc
  • MORE
Introduction

Diabetic Nephropathy - Overview

Diabetic Nephropathy - Therapeutics Development

Diabetic Nephropathy - Therapeutics Assessment

Diabetic Nephropathy - Companies Involved in Therapeutics Development

Diabetic Nephropathy - Drug Profiles

Diabetic Nephropathy - Dormant Projects

Diabetic Nephropathy - Discontinued Products

Diabetic Nephropathy - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Diabetic Nephropathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Diabetic Nephropathy - Pipeline by AbbVie Inc, H1 2018

Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H1 2018

Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H1 2018

Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H1 2018

Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H1 2018

Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H1 2018

Diabetic Nephropathy - Pipeline by Bayer AG, H1 2018

Diabetic Nephropathy - Pipeline by BLR Bio LLC, H1 2018

Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Diabetic Nephropathy - Pipeline by Cellmid Ltd, H1 2018

Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H1 2018

Diabetic Nephropathy - Pipeline by CSL Ltd, H1 2018

Diabetic Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, H1 2018

Diabetic Nephropathy - Pipeline by Dynamis Therapeutics Inc, H1 2018

Diabetic Nephropathy - Pipeline by Galectin Therapeutics Inc, H1 2018

Diabetic Nephropathy - Pipeline by GenKyoTex SA, H1 2018

Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H1 2018

Diabetic Nephropathy - Pipeline by GNI Group Ltd, H1 2018

Diabetic Nephropathy - Pipeline by Inspyr Therapeutics Inc, H1 2018

Diabetic Nephropathy - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018

Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2018

Diabetic Nephropathy - Pipeline by MediPost Co Ltd, H1 2018

Diabetic Nephropathy - Pipeline by Merck & Co Inc, H1 2018

Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H1 2018

Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Diabetic Nephropathy - Pipeline by MorphoSys AG, H1 2018

Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2018

Diabetic Nephropathy - Pipeline by Paranta Biosciences Ltd, H1 2018

Diabetic Nephropathy - Pipeline by PhiloGene Inc, H1 2018

Diabetic Nephropathy - Pipeline by PhytoHealth Corp, H1 2018

Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc, H1 2018

Diabetic Nephropathy - Pipeline by Redx Pharma Plc, H1 2018

Diabetic Nephropathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Diabetic Nephropathy - Pipeline by Sarfez Pharmaceuticals Inc, H1 2018

Diabetic Nephropathy - Pipeline by Serodus ASA, H1 2018

Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, H1 2018

Diabetic Nephropathy - Pipeline by Theravance Biopharma Inc, H1 2018

Diabetic Nephropathy - Pipeline by Torrent Pharmaceuticals Ltd, H1 2018

Diabetic Nephropathy - Pipeline by Twoxar Inc, H1 2018

Diabetic Nephropathy - Pipeline by Ube Industries Ltd, H1 2018

Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H1 2018

Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H1 2018

Diabetic Nephropathy - Dormant Projects, H1 2018

Diabetic Nephropathy - Dormant Projects, H1 2018 (Contd..1), H1 2018

Diabetic Nephropathy - Dormant Projects, H1 2018 (Contd..2), H1 2018

Diabetic Nephropathy - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Diabetic Nephropathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Antisense Therapeutics Ltd
  • Aptevo Therapeutics Inc
  • Araim Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • BLR Bio LLC
  • Boehringer Ingelheim GmbH
  • Cellmid Ltd
  • ChemoCentryx Inc
  • CSL Ltd
  • Daiichi Sankyo Co Ltd
  • DiaMedica Therapeutics Inc
  • Dynamis Therapeutics Inc
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • Gilead Sciences Inc
  • GNI Group Ltd
  • Inspyr Therapeutics Inc
  • Ironwood Pharmaceuticals Inc
  • Johnson & Johnson
  • MediPost Co Ltd
  • Merck & Co Inc
  • Mesoblast Ltd
  • Mitsubishi Tanabe Pharma Corp
  • MorphoSys AG
  • Noxxon Pharma AG
  • Paranta Biosciences Ltd
  • PhiloGene Inc
  • PhytoHealth Corp
  • ProMetic Life Sciences Inc
  • Redx Pharma Plc
  • Regeneron Pharmaceuticals Inc
  • Sarfez Pharmaceuticals Inc
  • Serodus ASA
  • Teijin Pharma Ltd
  • Theravance Biopharma Inc
  • Torrent Pharmaceuticals Ltd
  • Twoxar Inc
  • Ube Industries Ltd
  • Vascular Pharmaceuticals Inc
  • Vicore Pharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll